Everolimus Treatment of Renal Angiomyolipomas in Patient with Tuberous Sclerosis Complex
Journal of Urologic Oncology 2014³â 12±Ç 2È£ p.83 ~ p.85
¾È¼ºÈÆ(Ahn Sung-Hoon) - Wonkwang University School of Medicine Department of Urology
¿ÀÅÂÈÆ(Oh Tae-Hoon) - Wonkwang University School of Medicine Department of Urology
ÀÌ¿µÈ¯(Lee Young-Hwan) - Wonkwang University School of Medicine Department of Radiology
¼ÀÏ¿µ(Seo Ill-Young) - Wonkwang University School of Medicine Department of Urology
Abstract
Although embolization or nephron-sparing surgery may be recommended for large angiomyolipoma (AML) associated with bleeding, bilateral multiple AMLs in patients who are in-operable and preservation of renal function are complicated situations. Mammalian target of rapamycin (mTOR) inhibitor is considered as an alternative and less invasive treatment for AML in patients with tuberous sclerosis complex (TSC). We experienced a case of bilateral multiple AMLs in a 43-year-old woman with TSC. We treated her with everolimus. After 6 months of the medication, her facial angiofibromas were improved considerably, and gross hematuria and abdominal pain had disappeared. Follow-up computed tomography showed that the masses had decreased in size and presented a regression state.
Å°¿öµå
Tuberous sclerosis complex, Renal angiomyolipoma, Everolimus
KMID :
1001020140120020083
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)